GLP-1 / FGF21 dual
AP026 / TQA2226
1 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
1
Ongoing
0
Recruiting
0
Completed
0
Sites
1
Countries
1
Endpoints
18
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
1
Trials by status
Terminated
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
16
Other (unclassified)
2
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT06143423A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects. | AP026 / TQA2226 Type 2 diabetes | - | Ph 1 | Terminated | 1 | Jul 2023 | - |
Showing 1-1 of 1 trials